Health and Fitness Health and Fitness
Thu, December 2, 2010
[ Thu, Dec 02nd 2010 ] - Market Wire
Health Net Federal Services and the USO of Metrop .. ington Team Up for Annual Celebration of Children
[ Thu, Dec 02nd 2010 ] - Market Wire
Insmed Incorporated and Transave, Inc. Announce Business Combination
[ Thu, Dec 02nd 2010 ] - Market Wire
Apricus Biosciences bestimmt Produzenten fr Vitar .. edikament zur Behandlung von Erektionsstrungen in
[ Thu, Dec 02nd 2010 ] - Market Wire
Apricus Biosciences nomina il produttore canadese .. di nuova approvazione per il trattamento della di
[ Thu, Dec 02nd 2010 ] - Market Wire
Apricus Biosciences stelt producent aan voor Vita .. de geneesmiddel voor erectiestoornissen in Canada
Wed, December 1, 2010
[ Wed, Dec 01st 2010 ] - Market Wire
Amsterdam Molecular Therapeutics Amends Amgen GDNF Gene License Agreement
[ Wed, Dec 01st 2010 ] - Market Wire
Accuray Incorporated, Varian Medical, TomoTherapy, GlaxoSmithKline Plc and Theravance
[ Wed, Dec 01st 2010 ] - Market Wire
MannKind to Present at the Canaccord Genuity 5th .. ual Cardiovascular, Diabetes & Obesity Conference
[ Wed, Dec 01st 2010 ] - Market Wire
Exelixis Announces Webcast of Annual R&D Day on December 2
[ Wed, Dec 01st 2010 ] - Market Wire
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
[ Wed, Dec 01st 2010 ] - Market Wire
Apricus Biosciences Appoints Manufacturer for Vit .. oved Drug to Treat Erectile Dysfunction in Canada
[ Wed, Dec 01st 2010 ] - Market Wire
CIGNA Announces Tender Offer for any and all of its 8.50% Senior Notes due 2019
[ Wed, Dec 01st 2010 ] - Market Wire
Bristol-Myers Squibb and Alvin Ailey American Dan .. -Its-Kind Collaboration to Express the Stories of
[ Wed, Dec 01st 2010 ] - Market Wire
Oncolytics Biotech® Inc. Announces Start of .. lment in Randomized Phase II Ovarian Cancer Study
[ Wed, Dec 01st 2010 ] - Market Wire
Medisafe 1 Technologies Locking Syringe Adds ERP Compatibility Feature
[ Wed, Dec 01st 2010 ] - Market Wire
Aetna Names Michael Mathias Chief Information Officer
[ Wed, Dec 01st 2010 ] - Market Wire
CytRx Initiating Phase 2b Clinical Trial with Tamibarotene in Advanced Lung Cancer
[ Wed, Dec 01st 2010 ] - Market Wire
Genzyme Completes Sale of Genetic Testing Business to LabCorp
[ Wed, Dec 01st 2010 ] - Market Wire
LabCorp Successfully Completes Acquisition of Genzyme Genetics
[ Wed, Dec 01st 2010 ] - Market Wire
Synovis Life Technologies Reports 21 Percent Year .. ear Revenue Growth for Fiscal 2010 Fourth Quarter
[ Wed, Dec 01st 2010 ] - Market Wire
Allos Therapeutics Announces FOLOTYN® Data to Be .. t the 2010 Chicago Multidisciplinary Symposium in
[ Wed, Dec 01st 2010 ] - Market Wire
MEDNAX Announces the Acquisition of Washington State Pediatric Critical Care Practice
[ Wed, Dec 01st 2010 ] - Market Wire
BioScrip Appoints David W. Froesel, Jr. as Execut .. President, Chief Financial Officer and Treasurer
[ Wed, Dec 01st 2010 ] - Market Wire
OSI Pharmaceuticals, Inc. Exercises Option under .. nd Translational Research Collaboration with AVEO
Tue, November 30, 2010
[ Tue, Nov 30th 2010 ] - Market Wire
Teva Announces $1 Billion Share Repurchase Program
[ Tue, Nov 30th 2010 ] - Market Wire
NeuroMetrix to Present at Canaccord Genuity 5th Cardiovascular, Diabetes & Obesity Conference
[ Tue, Nov 30th 2010 ] - Market Wire
Gilead Sciences to Present at the NASDAQ OMX 25th Investor Program
[ Tue, Nov 30th 2010 ] - Market Wire
HealthSpring, Inc. Completes Acquisition of Bravo Health, Inc.
[ Tue, Nov 30th 2010 ] - Market Wire
InSite Vision Names Timothy Ruane Chief Executive Officer
[ Tue, Nov 30th 2010 ] - Market Wire
Micromet to Present at the 2010 Piper Jaffray Healthcare Conference

Micromet to Present at the 2010 Piper Jaffray Healthcare Conference


Published on 2010-11-30 09:31:14 - Market Wire
  Print publication without navigation


BETHESDA, Md.--([ BUSINESS WIRE ])--Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that its management will present a company overview at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 11:30 a.m. EST. The presentation will be webcast live and available for replay from Micromet's website, [ www.micromet.com ], under the "Investors and Media" section.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Companya™s lead product candidate blinatumomab (MT103) is currently the subject of a pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at [ www.micromet.com ].

Contributing Sources